In this study, we propose that the levels of CD137+ T cells prior to immunotherapy, as a biomarker of immune activation, is able to predict the response and clinical outcome of (R/M) HNSCC patients to pembrolizumab treatment. The gene discussed is TNFRSF9; the disease is head and neck squamous cell carcinoma.